ESTRO Multidisciplinary Management of Breast Cancer 2017

Previous Page

Next Page

Page Background

Tole

rance of the

Ra

diotherapy of BC associated or not with

B

evacizumab

ToleRAB n= 65 (B+RT): National retrospective case-controls study

Pernin, et al, The Breast 2014